Results 11 to 20 of about 6,495,609 (392)
Immunological Reviews, 2005 Multiple Sclerosis (MS) is a condition about which one does not very often hear in Malta. This is understandable due to the low incidence of the disease in our islands, an incidence which is significantly lower than that of nearby Sicilian towns such as ...
Agius, Leslie
core +3 more sources
Nature Reviews Disease Primers, 2018 Multiple sclerosis is a potentially progressive, autoimmune neurologic disorder of the central nervous system, resulting from an autoimmune attack on central nervous system white matter. It is a leading cause of neurologic symptoms in young adults, with no known cure.
D. Reich, C. Lucchinetti, P. Calabresi
semanticscholar +12 more sources
Journal of Clinical Investigation, 2012 Multiple sclerosis (MS) is a chronic, complex neurological disease with a variable clinical course in which several pathophysiological mechanisms such as axonal/ neuronal damage, demyelination, inflammation, gliosis, remyelination and repair, oxidative injury and excitotoxicity, alteration of the immune system as well as biochemical disturbances and ...
Alyssa, Nylander, David A, Hafler
openaire +4 more sources
BMC Complementary Medicine and Therapies, 2021 Background The use of dietary and herbal supplements (DIHES) is widespread among people with multiple sclerosis (PwMS). PwMS are a highly informed patient group, and they use several types of sources to seek information on subjects related to their ...
Sofie Bergien +4 more
doaj +1 more source
Cell-based therapeutic strategies for multiple sclerosis. [PDF]
, 2017 The availability of multiple disease-modifying medications with regulatory approval to treat multiple sclerosis illustrates the substantial progress made in therapy of the disease.
Cohen, Jeffrey A +6 more
core +1 more source
Mental Health Clinician, 2019 Abstract Multiple sclerosis is a chronic, unpredictable, and disabling disease. Significant advances have been made in recent years supporting an earlier, more accurate, diagnosis and have led to more than 15 disease-modifying therapies approved by the Food and Drug Administration for relapsing forms of multiple sclerosis.
Shilpa Klocke, Nicole Hahn
openaire +4 more sources
Journal of Neuroinflammation, 2020 Background Targeting RNA polymerase-1 (POL1) machinery is a new strategy for suppression of multiple sclerosis (MS) relapse activity. Oral administration of POL1 inhibitor RAM-589.555, which is characterized by high permeability and bioavailability in ...
Rina Zilkha-Falb +4 more
doaj +1 more source
A grounded theory analysis of the occupational impact of caring for a partner who has multiple sclerosis [PDF]
, 2006 Chronic progressive conditions such as multiple sclerosis impact engagement in and orchestration of daily occupations by people with the condition, and their family members.
Gough, B, Heward, K, Molineaux, M
core +1 more source
Gut Microbiome in Progressive Multiple Sclerosis
Annals of Neurology, 2021 This study was undertaken to investigate the gut microbiome in progressive multiple sclerosis (MS) and how it relates to clinical disease.
Laura M. Cox +17 more
semanticscholar +1 more source
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Annals of Neurology, 2011 New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis of multiple sclerosis. The use of imaging for demonstration of dissemination of central nervous system lesions in space and time has been simplified, and in ...
C. Polman +17 more
semanticscholar +1 more source